Compass Financial Management
RXRX icon

Compass Financial Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Compass Financial Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.87K Hold
694
– – ﹤0.01% 1398
2026
Q2 		$2.55K Buy
+694
New +$2.31K ﹤0.01% 1288

Other funds holding RXRX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
MIC Capital Management (UK)
MIC Capital Management (UK) London, United Kingdom $463M AUM 7.9% 1-Year Est. Return

Compass Financial Management's RXRX Position: Q3 2026 in Review

Compass Financial Management held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 694 shares worth $2.87K. The position accounts for ﹤0.01% of the portfolio, ranked #1398.

Compass Financial Management first reported a position in RXRX in Q2 2026 and has held it in 2 quarters since. 264 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Compass Financial Management held 694 shares of Recursion Pharmaceuticals worth $2.87K as of Q3 2026.
  • Compass Financial Management left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Compass Financial Management's portfolio in Q3 2026, its #1398 holding.
  • Compass Financial Management first reported a position in Recursion Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 264 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Compass Financial Management's 13F filing for Q3 2026, filed 30 Oct 2026.